We are proud to announce that PhenoPath is now part of AmeriPath.
This is a send out panel. Probes vary by vendor, and Client may be billed for the testing. Contact PhenoPath Client Services for details.
Methodology: Send out test
Two recurrent genetic abnormalities that occur in acute lymphoblastic leukemia (ALL) include the t(9;22) BCR/ABL and MLL gene rearrangements. “Ph+” ALL cases are more common in adults than children, but when present in either group portend a worse prognosis. Such cases that are Ph+ have been shown to be responsive to BCR/ABL targeted therapies such as imatinib. The t(v;11q23); MLL rearranged group refer to ALL cases which harbor an MLL translocation with one of a large group of partners. Such cases are best detected by an MLL breakapart FISH probe that detects any MLL rearrangement but does not distinguish between any specific type. MLL translocations may occur in utero and these types of ALL cases are the most common in infants less than 1 year of age. The presence of an MLL rearrangement generally portends a worse prognosis and higher risk of treatment failure.
Disease State: Precursor B-Lymphoblastic Lymphoma/Leukemia (B-ALL)
CPT Code(s): Variable, depending on where specimen is sent; contact Client Services for additional information
Turnaround Time: Variable, depending on where specimen is sent; contact Client Services for additional information
Schedule: Monday - Friday
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Fresh tissue in RPMI